Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — Credit Suisse 2010 Healthcare Conference
12 slides from Teva Pharmaceutical Industries's conference presentation, Nov 11, 2010
Slide 1: Credit Suisse 2010 Healthcare Conference
Credit Suisse 2010 Healthcare Conference William Marth, President & CEO, Teva - Americas November 11, 2010
Slide 2: Forward Looking Statement
Forward Looking Statement This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause
Slide 3: Q3 2010 – exceptional margins
Q3 2010 – exceptional margins Q3/09* Q3/10* Change Sales ($m) 3,550 4,250 +20% Operating income ($m) 997 1,439 +44% Net income ($m) 806 1,182 +47% EPS ($) 0.89 1.30 +46% Operating cash flow ($m) 1,025 1,194 +16% Gross margin (%) 58.2 62.5 Operating margin (%) 28.1 33.9 Net margin (%) 22.7 27.8 *Net
Slide 4: Record cash flow
Record cash flow $ million 1,194 Cash from operations 1,025 161 957 954 195 886 167 179 90 Capex less sale 164 126 164 of assets 141 165 Dividends 866 704 637 700 557 Free cash flow Q3'09 Q4'09 Q1'10 Q2'10 Q3'10
Slide 5: Targets for 2015
Targets for 2015 Revenues $31B Net income $6.8B Net profitability 22% r y 2010 r Ja nua ou iew From ategy Rev Str 5
Slide 6: Where Are We Now? Interim Update
Where Are We Now? Interim Update $31B CAGR = 14% $16.4B $15.8 B $13.9B International Europe US USD Billion 2009 2010E 2015E Source: Company filings and analysts’ reports We make better healthcare accessible around the world 6
Slide 7: Growing demand for generics
Growing demand for generics Market outlook for global generic sales Source: Exane BNP Paribas, IMS, Espicom, Teva estimates
Slide 8: Largest pipeline among U.S. generics players
Largest pipeline among U.S. generics players U.S., October 26, 2010 $118bn $55bn brand sales brand sales
Slide 9: Teva Branded – Multifaceted Approach
Teva Branded – Multifaceted Approach 9
Slide 10: Teva Branded – From $4.2 Billion to $9.2 Billion
Teva Branded – Multifaceted Approach From $4.2 Billion to $9.2 Billion 10
Slide 11: Teva Branded – Multifaceted Approach
Teva Branded – Multifaceted Approach Sales 2009 = $4.2 bn Sales 2015 = $9.2 bn How will we get there? 1. Organic growth 2. Pipeline 3. Acquisitions/licensing BioS, 9% BioS, 2% Women’s health 12% Women’s health Innovative 17% Respiratory 48% 22% Innovative 64% Respiratory 26%
Slide 12: Loaded Branded Pipeline
Loaded Branded Pipeline Marketed Products End Phase III 2010-2012 End Phase III 2013-2015 TV-1101 (OGX-011) 3 oncological projects (Phase III) Laquinimod DiaPep-277 Oral Multiple Sclerosis (Phase III) Type I Diabetes (Phase III) Copaxone® StemEx® Laquinimod Multiple Sclerosis & CIS Hemato-oncologica
Teva Pharmaceutical Industries — Credit Suisse 2010 Healthcare Conference on 6ix